Compare GSK plc (GSK) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kinross Gold Corporation — how do they compare? GSK plc trades at $52.73 (market cap $101.34B), while Kinross Gold Corporation trades at $22.93 (market cap $27.94B). The key difference: GSK plc is far larger — about 3.6× Kinross Gold Corporation's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | KGC | |
|---|---|---|
Market Cap | $101.34B | $27.94B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $38.06 |
52-Week Low | $36.20 | $15.33 |
Enterprise Value | $121.95B | $26.49B |
Dividend Yield | 3.49% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Kinross Gold (KGC) trades at $22.87, down 4.35% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue at $7.05 billion and net income of $2.39 billion, supported by a P/E of 10.07 and ROE of 35.15%. Recent earnings beats and a consensus analyst price target of $37.20 suggest undervaluation, while technical indicators highlight near-term pressure with key support at $23.
KGC presents a compelling value opportunity with solid profitability and growth prospects, though risks include gold price volatility and rising costs. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q2 2026 earnings due July 29 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
